These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies. Yang Z; Deng W; Zhang X; An Y; Liu Y; Yao H; Zhang Z Front Oncol; 2021; 11():789330. PubMed ID: 35083147 [TBL] [Abstract][Full Text] [Related]
23. [Vascular perfusion as the origin of neoplasm resistance to radio- and chemotherapy]. Martinive P; Coucke PA Rev Med Liege; 2010 Mar; 65(3):133-9. PubMed ID: 20411817 [TBL] [Abstract][Full Text] [Related]
24. Modulation of the tumor vasculature and oxygenation to improve therapy. Siemann DW; Horsman MR Pharmacol Ther; 2015 Sep; 153():107-24. PubMed ID: 26073310 [TBL] [Abstract][Full Text] [Related]
30. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407 [TBL] [Abstract][Full Text] [Related]
31. Tumour blood vessel normalisation by prolyl hydroxylase inhibitor repaired sensitivity to chemotherapy in a tumour mouse model. Koyama S; Matsunaga S; Imanishi M; Maekawa Y; Kitano H; Takeuchi H; Tomita S Sci Rep; 2017 Mar; 7():45621. PubMed ID: 28361934 [TBL] [Abstract][Full Text] [Related]
32. The Anti-Colon Cancer Effects of Essential Oil of Feng Y; Deng L; Guo H; Zhao Y; Peng F; Wang G; Yu C Front Oncol; 2021; 11():728464. PubMed ID: 34765545 [TBL] [Abstract][Full Text] [Related]
33. Angiogenesis and angiogenesis inhibitors in cancer. Giavazzi R; Taraboletti G Forum (Genova); 1999; 9(3):261-72. PubMed ID: 10504172 [TBL] [Abstract][Full Text] [Related]
34. The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. Moore C; Kosgodage U; Lange S; Inal JM Int J Cancer; 2017 Aug; 141(3):428-436. PubMed ID: 28247946 [TBL] [Abstract][Full Text] [Related]
35. Broad targeting of angiogenesis for cancer prevention and therapy. Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295 [TBL] [Abstract][Full Text] [Related]
36. The role of the tumour microenvironment in immunotherapy. Gasser S; Lim LHK; Cheung FSG Endocr Relat Cancer; 2017 Dec; 24(12):T283-T295. PubMed ID: 28754821 [TBL] [Abstract][Full Text] [Related]
37. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G Novartis Found Symp; 2007; 283():106-20; discussion 121-5, 238-41. PubMed ID: 18300417 [TBL] [Abstract][Full Text] [Related]
38. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Noman MZ; Hasmim M; Lequeux A; Xiao M; Duhem C; Chouaib S; Berchem G; Janji B Cells; 2019 Sep; 8(9):. PubMed ID: 31540045 [TBL] [Abstract][Full Text] [Related]